Betulinic acid-induced apoptosis in leukemia cells

Leukemia

Volumn 18, Issue 8, 2004, Pages 1406-1412

  Ehrhardt, H ^a   Fulda, S ^b   Fuhrer M ^a   Debatin, Klaus Michael ^b   Jeremias, I ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; Betulinic acid; Leukemia

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ASPARAGINASE; BETULIC ACID; CASPASE; CYTARABINE; CYTOCHROME C; CYTOKINE RECEPTOR; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TIOGUANINE; VINCRISTINE;

ACUTE LEUKEMIA; ADOLESCENT; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CELL ISOLATION; CELL SECRETION; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA CELL LINE; MALE; MITOCHONDRION; NEUROECTODERM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STANDARD;

EID: 4344609047     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403406     Document Type: Article

References (22)

1. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1995; 1: 1046-1051.
2. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 2002; 175: 17-25.
3. Kim JY, Koo HM, Kim DS. Development of C-20 modified betulinic acid derivates as antitumor agents. Bioorg Med Chem Lett 2001; 11: 2405-2408.
4. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M et al. Betulinic acid triggers CD95 (Apo-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-4964.
5. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998; 58: 4453-4460.
6. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998; 273: 33942-33948.
7. Syrovets T, Buchele B, Gedig E, Slupsky JR, Simmet T. Acetylboswellic acids are novel catalytic inhibitors of human topoisomerases I and IIα. Mol Pharmacol 2000; 58: 71-78.
8. Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species and caspase processing. J Pharmacol Exp Ther 1999; 289: 1306-1312.
9. Fulda S, Strauss G, Meyer E, Debatin KM. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000; 95: 301-308.
10. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL-mediated survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis by NFκB. Oncogene 2003; 22: 3842-3852.
11. Armstrong RC, Aja T, Xiang J, Gaur S, Krebs JF, Hoang K et al. Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 1996; 271: 16850-16855.
12. Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J 1996; 15: 6189-6196.
13. Harhaj EW, Good L, Xiao G, Uhlik M, Cvijic ME, Rivera-Walsh I et al. Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein. Oncogene 2000; 19: 1448-1456.
14. Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J. Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 2001; 167: 3164-3173.
15. Henderson PJ, Lardy HA. Bongkrekic acid. An inhibitor of the adenine nucleotide translocase of mitochondria. J Biol Chem 1970; 245: 1319-1326.
16. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314: 471-477.
17. Kitchen BJ, Balis FM, Poplack DG, O'Brien M, Craig CE, Adamson PC. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion. Clin Cancer Res 1997; 3: 713-717.
18. Harris AL, Potter C, Bunch C, Boutagy J, Harvey DJ, Grahame-Smith DG. Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol 1979; 8: 219-227.
19. Edick MJ, Gajjar A, Mahmoud HH, van de Poll ME, Harrison PL, Panetta JC et al. Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 1340-1346.
20. Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukemia. Br J Haematol 2000; 110: 780-790.
21. Wagner T, Heydrich D, Voelcker G, Hohorst HJ. Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man. J Cancer Res Clin Oncol 1980; 96: 79-92.
22. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574-577.